Skip to content

McKesson MCK Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Cencora logo
CencoraCOR
$1.09B+30,738%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$61.6M+2.0%
Viatris logo
ViatrisVTRS
-$47.5M+52.2%
The Oncology Institute, Inc. logo
The Oncology Institute, Inc.TOI
$4.02M+142%
Medline, Inc.
 logo
Medline, Inc. MDLN
-$131M+43.8%

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$88.46B-1.9%
Enterprise value$86.77B-12.1%
P/E18.6×-9.9×
P/S0.2×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: McKesson’s 10-K, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about McKesson's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is McKesson's other income (expense)?
McKesson (MCK) reported other income (expense) of $36M in Q1 2026.
What is the long-term trend for McKesson's other income (expense)?
Over 3 years (2022 to 2026), McKesson's other income (expense) has grown at a -3.1% compound annual growth rate (CAGR), from $259M to $236M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.